首页 | 本学科首页   官方微博 | 高级检索  
     


SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Authors:Katherine R. Tuttle  Frank C. Brosius  Matthew A. Cavender  Paola Fioretto  Kevin J. Fowler  Hiddo J.L. Heerspink  Tom Manley  Darren K. McGuire  Mark E. Molitch  Amy K. Mottl  Leigh Perreault  Sylvia E. Rosas  Peter Rossing  Laura Sola  Volker Vallon  Christoph Wanner  Vlado Perkovic
Affiliation:1. Providence Health Care and University of Washington School of Medicine, Spokane, WA;2. University of Arizona College of Medicine, Tucson, AZ;3. University of North Carolina School of Medicine, Chapel Hill, NC;4. Department of Medicine, University of Padua, Italy;5. The Voice of the Patient, Inc, Elmhurst, IL;6. University of Groningen, Groningen, the Netherlands;7. National Kidney Foundation, New York, NY;8. University of Texas Southwestern Medical Center, Dallas, TX;9. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern, University Feinberg School of Medicine, Chicago, IL;10. University of Colorado Anschutz Medical Campus, Aurora, CO;11. Joslin Diabetes Center and Harvard Medical School, Boston, MA;12. Steno Diabetes Center Copenhagen, Gentofte;13. University of Copenhagen, Copenhagen, Denmark;14. University of the Republic, Montevideo, Uruguay;15. University of California-San Diego, La Jolla, CA;16. Division of Nephrology, University Hospital Würzburg, Würzburg, Germany;17. George Institute for Global Health, UNSW Sydney, Australia
Abstract:
Keywords:Hyperglycemia  diabetic kidney disease (DKD)  heart failure (HF)  atherosclerotic cardiovascular disease (ASCVD)  major adverse cardiovascular events (MACE)  sodium/glucose cotransporter 2 (SGLT2)  SGLT2 inhibitor  renal function preservation  kidney protection  research priorities  review
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号